Top Qs
Timeline
Chat
Perspective
Seclidemstat
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
Seclidemstat is an investigational new drug that is being evaluated for the treatment of cancer.[1] It is non-covalent small-molecule inhibitor of lysine-specific demethylase 1 (LSD1, KDM1A) investigated for cancer therapy, including Ewing sarcoma, SWI/SNF-mutated ovarian cancers, and advanced solid tumors. By blocking both the enzymatic and scaffolding functions of LSD1, especially its interactions within transcriptional regulatory complexes such as CoREST, Seclidemstat reprograms gene expression patterns that sustain tumor proliferation and immune evasion. It is among the handful of LSD1 inhibitors to reach clinical trials, with research focusing on its anticancer activity and potential immune modulatory effects in the tumor microenvironment. Ongoing challenges in development have included both efficacy and safety in early-phase studies as identified across the class of LSD1 inhibitors.[2]
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads